001     168369
005     20240229133606.0
024 7 _ |a 10.1007/s00520-021-06132-w
|2 doi
024 7 _ |a pmid:33847829
|2 pmid
024 7 _ |a 0941-4355
|2 ISSN
024 7 _ |a 1433-7339
|2 ISSN
024 7 _ |a altmetric:103839381
|2 altmetric
037 _ _ |a DKFZ-2021-00858
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Adam, Salome
|b 0
245 _ _ |a Identifying classes of the pain, fatigue, and depression symptom cluster in long-term prostate cancer survivors-results from the multi-regional Prostate Cancer Survivorship Study in Switzerland (PROCAS).
260 _ _ |a New York,NY
|c 2021
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1634302319_1829
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a #LA:C071# / 2021 Nov;29(11):6259-6269
520 _ _ |a Aside from urological and sexual problems, long-term (≥5 years after initial diagnosis) prostate cancer (PC) survivors might suffer from pain, fatigue, and depression. These concurrent symptoms can form a cluster. In this study, we aimed to investigate classes of this symptom cluster in long-term PC survivors, to classify PC survivors accordingly, and to explore associations between classes of this cluster and health-related quality of life (HRQoL).Six hundred fifty-three stage T1-T3N0M0 survivors were identified from the Prostate Cancer Survivorship in Switzerland (PROCAS) study. Fatigue was assessed with the EORTC QLQ-FA12, depressive symptoms with the MHI-5, and pain with the EORTC QLQ-C30 questionnaire. Latent class analysis was used to derive cluster classes. Factors associated with the derived classes were determined using multinomial logistic regression analysis.Three classes were identified: class 1 (61.4%) - 'low pain, low physical and emotional fatigue, moderate depressive symptoms'; class 2 (15.1%) - 'low physical fatigue and pain, moderate emotional fatigue, high depressive symptoms'; class 3 (23.5%) - high scores for all symptoms. Survivors in classes 2 and 3 were more likely to be physically inactive, report a history of depression or some other specific comorbidity, be treated with radiation therapy, and have worse HRQoL outcomes compared to class 1.Three distinct classes of the pain, fatigue, and depression cluster were identified, which are associated with treatment, comorbidities, lifestyle factors, and HRQoL outcomes. Improving classification of PC survivors according to severity of multiple symptoms could assist in developing interventions tailored to survivors' needs.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
650 _ 7 |a Classes
|2 Other
650 _ 7 |a Depression
|2 Other
650 _ 7 |a Fatigue
|2 Other
650 _ 7 |a Pain
|2 Other
650 _ 7 |a Prostate cancer
|2 Other
650 _ 7 |a Symptom cluster
|2 Other
700 1 _ |a Thong, Melissa
|0 P:(DE-He78)24fe6057396bec79d2638615b12eb989
|b 1
|u dkfz
700 1 _ |a Martin-Diener, Eva
|b 2
700 1 _ |a Camey, Bertrand
|b 3
700 1 _ |a Egger Hayoz, Céline
|b 4
700 1 _ |a Konzelmann, Isabelle
|b 5
700 1 _ |a Mousavi, Seyed Mohsen
|b 6
700 1 _ |a Herrmann, Christian
|b 7
700 1 _ |a Rohrmann, Sabine
|b 8
700 1 _ |a Wanner, Miriam
|b 9
700 1 _ |a Staehelin, Katharina
|b 10
700 1 _ |a Strebel, Räto T
|b 11
700 1 _ |a Randazzo, Marco
|b 12
700 1 _ |a John, Hubert
|b 13
700 1 _ |a Schmid, Hans-Peter
|b 14
700 1 _ |a Feller, Anita
|b 15
700 1 _ |a Arndt, Volker
|0 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
|b 16
|e Last author
|u dkfz
773 _ _ |a 10.1007/s00520-021-06132-w
|0 PERI:(DE-600)1463166-0
|n 11
|p 6259-6269
|t Supportive care in cancer
|v 29
|y 2021
|x 1433-7339
909 C O |p VDB
|o oai:inrepo02.dkfz.de:168369
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 1
|6 P:(DE-He78)24fe6057396bec79d2638615b12eb989
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 16
|6 P:(DE-He78)d023fdf423d87ee6c710e34dd7581fa0
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
913 0 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-313
|3 G:(DE-HGF)POF3
|2 G:(DE-HGF)POF3-300
|4 G:(DE-HGF)POF
|v Cancer risk factors and prevention
|x 0
914 1 _ |y 2021
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-01-26
|w ger
915 _ _ |a DEAL Springer
|0 StatID:(DE-HGF)3002
|2 StatID
|d 2021-01-26
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2021-01-26
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-26
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b SUPPORT CARE CANCER : 2019
|d 2021-01-26
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-26
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-26
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-01-26
920 1 _ |0 I:(DE-He78)C071-20160331
|k C071
|l C071 Cancer Survivorship
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C071-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21